We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Liraglutide (GLP-1 receptor agonist)
An FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Prescription medication — not a dietary supplement
Liraglutide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Liraglutide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2009–2026 with a typical study size of 3,731 participants.
Based on 436 studies · 73 meta-analyses · 334 RCTs · 33,326 total participants
Confidence
High confidenceBy outcome
Scored 'Strong' (7.5) because large phase-3 RCTs and a dedicated outcomes trial consistently prove glycemic, weight, and cardiovascular benefit; not higher because it is a prescription drug with real risks and weaker weight loss than semaglutide.
339 randomised trials
92% were about Liraglutide in an audit of 50 of them
Every randomised or controlled trial of Liraglutide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
46 trials ongoing or recruiting · 367 completed on ClinicalTrials.gov
137 of the completed trials have posted results
Registered trials show research momentum for Liraglutide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Liraglutide is a once-daily acylated analogue of the gut incretin hormone GLP-1 (glucagon-like peptide-1).
It is a prescription drug, NOT a dietary supplement: branded as Victoza (subcutaneous, type 2 diabetes) and Saxenda (subcutaneous 3.0 mg, chronic weight management), and FDA-approved in the US for these indications. EU products and indications must be checked against the corresponding EU product information.
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), the brain (appetite suppression and satiety), and the gut (slowed gastric emptying).
The evidence base is one of the stronger ones on this site, anchored by large phase-3 randomized controlled trials.
In type 2 diabetes the LEAD program established efficacy: LEAD-3 Mono (746 patients) showed liraglutide 1.8 mg cut HbA1c by 1.14% vs 0.51% for glimepiride over 52 weeks; LEAD-6 showed it beat exenatide head-to-head on glycemic control.
The landmark LEADER cardiovascular-outcomes trial (9,340 patients with type 2 diabetes at high cardiovascular risk, median 3.8 years) found a significant 13% relative reduction in the composite of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.87; 95% CI 0.78-0.97; P=0.01 for superiority), a 22% reduction in cardiovascular death (HR 0.78), and a 15% reduction in all-cause death (HR 0.85).
For weight management, the SCALE Obesity trial (3,731 adults without diabetes) produced a mean 8.4 kg loss vs 2.8 kg on placebo at 56 weeks (−5.6 kg difference), with 63% vs 27% losing ≥5%; SCALE Diabetes confirmed a 6.0% weight loss in people with type 2 diabetes; and in prediabetes a 3-year SCALE trial delayed progression to type 2 diabetes (HR 0.21).
It is effective but, head-to-head, less potent for weight loss than once-weekly semaglutide.
In the US, FDA labeling for liraglutide carries a boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma) and under that US label is contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2; it carries risks of pancreatitis and gallbladder disease; gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common; weight loss includes loss of lean muscle; and the FDA has warned about dosing errors and impurities in compounded/grey-market GLP-1 products.
It should be used only under a clinician's care, for a genuine medical indication — not as a cosmetic shortcut.
A once-daily, albumin-bound analogue of the incretin hormone GLP-1 that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the single upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce energy intake — the primary driver of the weight loss seen in the SCALE trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the nausea seen in trials.
How Liraglutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — under the US label, which carries a US FDA boxed warning for thyroid C-cell tumors. In Germany or Austria, the current product information for the exact medicine applies.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — discontinue if pregnancy is detected; weight loss is not advised during pregnancy.
Not appropriate — this is a prescription drug with real risks, not a cosmetic shortcut. Use only for a clinician-confirmed indication.
Prescription use under specialist care only, for obesity that has not responded to lifestyle therapy. In a 56-week trial of liraglutide 3.0 mg, gastrointestinal adverse events affected 64.8% against 36.5% on placebo, and 10.4% stopped treatment for adverse events against 0 on placebo. One suicide occurred on liraglutide, which the investigator judged unlikely to be related, so it is a trial event and not established causation. BMI rose again after treatment stopped.
Combining with insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Liraglutide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can change the absorption of co-administered oral drugs; clinician monitoring advised, especially for narrow-therapeutic-index medicines.
Do not combine with another GLP-1 agonist (e.g. semaglutide, dulaglutide, exenatide, tirzepatide) — additive risk with no added benefit.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: Clinician reduces background insulin/sulfonylurea dose; monitor blood glucose
Tip: Resistance training and adequate protein intake during weight loss
Liraglutide has an evidence score of 7.5/10 — strong evidence based on 436 indexed studies, including 3 meta-analyses. An FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended. Representative study: PMID 23163663.
Dosing for Liraglutide: Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Liraglutide — consistent daily use matters more than the time of day. Subcutaneous once daily at any time of day, with or without food, ideally at a consistent time.
Liraglutide should be used with caution — talk to a healthcare provider before taking it. Reported side effects include acute pancreatitis, gallbladder disease (cholelithiasis / cholecystitis), hypoglycemia (with insulin/sulfonylureas). How often they occur is not established for all of them. Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label); Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label); Prior serious hypersensitivity to liraglutide or any GLP-1 receptor agonist.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Dulaglutide
Too few graded studiesAn FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended.
Orforglipron
Too few graded studiesAn ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 436 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research